Disease relevance of Histiocytosis, Sinus

• Histiocytes in Rosai-Dorfman disease and hemophagocytic syndrome also coexpressed CCR6 and CCR7, suggesting that this may be a general attribute of abnormal histiocytes [1].
• Among hematopoietic disorders and nonhematopoietic neoplasms, CD163 expression was restricted largely to cases of chronic myelomonocytic leukemia, histiocytic sarcoma, sinus histiocytosis with massive lymphadenopathy, and littoral cell angioma [2].
• The presence of histiocytes showing lymphophagocytosis and positivity for S-100 protein staining confirmed that the lesions represented extranodal forms of sinus histiocytosis with massive lymphadenopathy [3].
• A fatal case of sinus histiocytosis with massive lymphadenopathy (SHML) is described in a male patient who presented at 11 years-of-age with swelling of the malar region and nasal obstruction due to the disease and who died aged 28 in uraemic coma following renal involvement [4].
• In the second pattern (two biopsies), paracortical hyperplasia was accompanied by massive sinus histiocytosis and S-100 positive histiocyte aggregates [5].

High impact information on Histiocytosis, Sinus

• Large pale histiocytes of Rosai-Dorfman disease are immunoreactive for S-100 protein and KP1, but negative for CD1a [6].
• We attempted to sequence TNFRSF6 DNA from archived tissue of 14 cases of Rosai-Dorfman disease [7].
• Dapsone as a potential treatment for cutaneous Rosai-Dorfman disease with neutrophilic predominance [8].
• Rosai-Dorfman disease in a patient with systemic lupus erythematosus [9].
• Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment [10].

Chemical compound and disease context of Histiocytosis, Sinus

• Steroid-responsive Rosai-Dorfman disease [11].
• Venorelbine and methotrexate for the treatment of Rosai-Dorfman disease [12].
• Extranodal Rosai-Dorfman disease with cutaneous, ophthalmic and laryngeal involvement: report of a case treated with isotretinoin [13].

Biological context of Histiocytosis, Sinus

• T status, age, menopausal status, histology, estrogen receptor status, nuclear grade, and sinus histiocytosis were evaluated as prognostic indicators [14].

Anatomical context of Histiocytosis, Sinus

• Intracellular fibronectin was observed in cases of reactive sinus histiocytosis, when about a third of macrophages exhibited strong positivity [15].
• Among the factors submitted to histologic evaluation, nuclear grade, INF, vessel involvement and lymph node metastasis were apparently correlated to prognosis, while sinus histiocytosis was not significantly related to it, except for patients with positive nodes [16].
• CONCLUSION: The lymph nodes of patients with H and N SCC are distinguished by T cell depletion and sinus histiocytosis (SH) [17].
• In contrast to LCH, class II histiocytosis is characterized by the proliferation of mononuclear phagocytes other than Langerhans cells and includes sinus histiocytosis with massive lymphadenopathy, viral-associated hemophagocytic syndrome, and familial hemophagocytic lymphohistiocytosis [18].

Gene context of Histiocytosis, Sinus

• Positivity for S-100 protein, alpha1-antitrypsin, alpha1-antichymotrypsin, lysozyme, Mac387 and CD68 proteins, and negativity for CD1a protein confirmed the diagnosis of Rosai-Dorfman disease [19].
• Clinical quiz. Large-cell anaplastic lymphoma coexisting with Rosai-Dorfman disease [20].
• Based on clinicopathological observations of 91 female patients with breast cancer in Miyagi Prefecture, TNM stage, histologic type, grade of infiltrative growth tendency (INV), vessel involvement, lymph node metastasis, nuclear grade and sinus histiocytosis were assessed in relation to prognosis [16].
• The lymph nodes of IRX-2-treated H and N SCC patients showed increased size (over both control groups), increased T cell area and density and decreased follicles and sinus histiocytosis [17].

References